Antiplatelet Therapy with Aspirin: From Clinical Trials to Practice

• References

• 1 Willard JE, Lange RA, Hillis LD. Current concepts: The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175-181
• 2 Goodnight SH, Coull BM, McAnulty JH, Taylor LM. Antiplatelet Therapy - Part 1 and 2. West I Med 1993; 158: part I 385-392-part II 506-514
• 3 Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: Theory and practice. Blood 1994; 83: 885-898
• 4 Patrono C. Drug therapy: Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
• 5 Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 659-675
• 6 Goodnight SH. Antiplatelet therapy in cardiovascular disease. In: Disorders of Thrombosis. Hull RD, Pineo GF. (eds). WB Saunders, Inc; Philadelphia: 1995. in press
• 7 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. (Parts 1 and 2). N Engl J Med 1992; 326: part I 242-250-part II 310-318
• 8 Underwood MJ, More RS. The aspirin papers. Br Med J 1994; 308: 71-72
• 9 Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy — I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106
• 10 Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129-135
• 11 Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford ID, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518
• 12 McCall NT, Tofler GH, Schafer AI, Williams GH, Muller JE. The effect of enteric-coated aspirin on the morning increase in platelet activity. Am Heart J 1991; 121: 1382-1388
• 13 Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82: 897-902
• 14 FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
• 15 Betteridge DJ, Cooper MB, Saggerson ED, Prichard BN C, Tan KC B, Ling E, Barbera G, McCarthy S, Smith CC T. Platelet function in patients with hypercholesterolaemia. Eur J Clin Invest 1994; (Suppl. 24) Suppl 1: 30-33
• 16 Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism J Clin Invest 1993; 92: 1400-1406
• 17 Van Kooten F, Ciabattoni G, Patrono C, Schmitz PI M, van Gijn J, Koudstaal PI. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994; 25: 278-281
• 18 Koudstaal PJ, Ciabattoni G, van Gijn J, Nieuwenhuis HK, de Groot PG, Sixma JJ, Patrono C. Increased thromboxane synthesis in patients with acute cerebral ischemia. Stroke 1993; 24: 219-223
• 19 Fitzgerald DJ, FitzGerald GA. Role of thrombin and thromboxane A₂in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989; 86: 7585-7589
• 20 Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989; 80: 1718-1725
• 21 Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
• 22 Chesebro JH, Webster MW I, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ. Antithrombotic therapy and progression of coronary artery disease: Antiplatelet versus antithrombins. Circulation 1992; (Suppl. 86) Suppl. 100-110
• 23 Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839
• 24 Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, Hennekens CH. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet 1992; 340: 143-145
• 25 Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993; 87: 1873-1879
• 26 Kopp E, Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science 1994; 265: 956-959
• 27 Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation 1994; 89: 503-505
• 28 Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809
• 29 Schwartz L, Lesperance J, Bourassa MG, Eastwood C, Kazim F, Arafah M, Ganassin L. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990; 119: 232-236
• 30 Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719
• 31 Goldman S, Copeland J, Moritz T. et al. Long-term graft patency (3 years) after coronary artery surgery: Effects of aspirin: Results of a VA Cooperative Study. Circulation 1994; 89: 1138-1143
• 32 Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetyl salicylic acid prevent stroke after carotid surgery. A double-blind, placebo-controlled randomized trial. Stroke 1993; 24: 1125-1128
• 33 Harker LA, Bernstein EF, Dilley RB, Scala TE, Sise MJ, Hye RJ, Otis SM, Roberts RS, Gent M. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med 1992; 116: 731-736
• 34 The Dutch TIA trial study group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266
• 35 Ranke C, Creutzig A, Luska G, Wagner H-H, Galanski M, Bode-Boger S, Frolich J, Avenarius H-J, Hecker H, Alexander K. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Invest 1994; 72: 673-680
• 36 Dyken ML, Barnett HJ M, Easton JD, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG. Low-dose aspirin and stroke: “It ain’t necessarily so”. Stroke 1992; 23: 1395-1399
• 37 Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994; 25: 275-277
• 38 Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A₂but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141
• 39 Charman WN, Charman SA, Monkhouse DC, Frisbee SE, Lockhart EA, Weisman S, FitzGerald GA. Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Br J Clin Pharmacol 1993; 36: 470-473
• 40 Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ. Transdermal modification of platelet function: A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 1993; 88: 556-561
• 41 Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function: Implications for clinical trials and therapy. Arch Pathol Lab Med 1994; 118: 801-804
• 42 Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336
• 43 Helgason CM, Hoff JA, Kondos GT, Brace LD. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993; 24: 1458-1461
• 44 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054
• 45 Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharm 1993; 35: 219-226
• 46 Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharm Therap 1993; 54: 84-89
• 47 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part II N Engl J Med 1992; 326: 310-318
• 48 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152
• 49 Report of the Sixty Plus Reinfarction Study Group: A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-993
• 50 Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-691
• 51 Stroke Prevention in Atrial Fibrillation Investigators: Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-539
• 52 Kretschmer G, Wenzl E, Piza F, Polterauer P, Ehringer H, Minar E, Schemper M. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 1987; 102: 453-459
• 53 Kretschmer G, Herbst F, Prager M, Sautner T, Wenzl E, Berla-kovich GA, Zekert F, Marosi L, Schemper M. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-1115
• 54 Do D-D, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiol 1994; 193: 567-571
• 55 Antiplatelet Trialists’ Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
• 56 ASPECT Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503
• 57 Cairns JA. Oral anticoagulants or aspirin after myocardial infarction. Lancet 1994; 343: 497-498
• 58 Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul P-J, Bousser M-G. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl I Med 1994; 331: 1474-1479
• 59 McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. J Vase Surg 1991; 13: 150-162
• 60 Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94: 101-111
• 61 Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-1541
• 62 Turpie AG G, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-529
• 63 Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 1992; 68: 1-6
• 64 Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 1989; 298: 493-496